Stockscreener 앱 받기
1.16
0.00%
0.00
시장 영업 전:
1.13
-0.03
-2.59%
전일 마감가:
$1.16
열려 있는:
$1.16
하루 거래량:
241.24K
Relative Volume:
1.74
시가총액:
$13.31M
수익:
$28.74M
순이익/손실:
$-31.60M
주가수익비율:
-0.2283
EPS:
-5.0805
순현금흐름:
$-19.30M
1주 성능:
+4.04%
1개월 성능:
-3.33%
6개월 성능:
-0.85%
1년 성능:
-60.14%
1일 변동 폭
$1.14
$1.195
1주일 범위
$1.07
$1.195
52주 변동 폭
$1.00
$5.50
바이오나노 지노믹스 Stock (BNGO) Company Profile
명칭
Bionano Genomics Inc
전화
(858) 888-7600
주소
9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Compare BNGO vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNGO
Bionano Genomics Inc
|
1.16 | 12.39M | 28.74M | -31.60M | -19.30M | -5.0805 |
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
바이오나노 지노믹스 Stock (BNGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-09-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-12 | 재개 | BTIG Research | Buy |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2021-06-16 | 개시 | BTIG Research | Buy |
| 2020-09-24 | 개시 | Ladenburg Thalmann | Buy |
| 2020-04-08 | 개시 | Oppenheimer | Outperform |
모두보기
바이오나노 지노믹스 주식(BNGO)의 최신 뉴스
Bionano Genomics Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026 - The Manila Times
Bionano's Q2 Results Webcast Will Stay Online for at Least 30 Days - Stock Titan
Bionano Genomics Inc (BNGO) Cash Flow - TradingKey
Bionano Genomics Inc (BNGO) Balance Sheet - TradingKey
BNGO|Bionano Genomics Inc|Price:1.110| - TradingKey
Bionano Genomics Inc (BNGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bionano Genomics Inc (BNGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bionano Genomics Inc|Price:1.110 - TradingKey
Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bionano Genomics Inc (BNGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BNGO|Bionano Genomics Inc|Price:1.075|Chg%:-0.005 - TradingKey
Bionano Genomics, Inc. Revenue Breakdown – BMV:BNGO - TradingView
Bionano Genomics Inc (BNGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BNGO Q2'26 Earnings: revenue estimate is 7.48M USD - TradingView
Number of shareholders of Bionano Genomics, Inc. – GETTEX:2Y3 - TradingView
Precision Trading with Bionano Genomics Inc. (BNGO) Risk Zones - Stock Traders Daily
BNGO Q1 2026 Earnings: EPS Surprises to the Upside Amidst Revenue UncertaintyHealthcare Earnings Report - dars.gov.et
Nabsys selects first-ever chief medical officer - Providence Business News
BNGO Q1 2026 Earnings: EPS Surpasses Estimates, but Revenue Remains UnreportedEarnings Preview - DonanımHaber
Price to sales forward of Bionano Genomics, Inc. – NASDAQ:BNGO - TradingView
Bionano Genomics (BNGO) Edges Higher Amid Continued ConsolidationIceberg Order - dars.gov.et
BNGO Should I Buy - Intellectia AI
Bionano Genomics, Inc. (BNGO) reports Q1 loss, tops revenue estimates - MSN
Bionano Genomics, Inc. Actuals & Estimates (NASDAQ:BNGO) - TradingView
BNGO Forecast — Price Target — Prediction for 2027 - TradingView
Bionano Genomics, Inc. Announces Appointment of Alex Hastie to Chief Scientific Officer, Effective July 20, 2026 - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Bionano Genomics Names Alex Hastie Chief Scientific Officer - The Globe and Mail
Bionano Genomics appoints Alex Hastie as chief scientific officer - Investing.com UK
Bionano Genomics appoints Alex Hastie as chief scientific officer By Investing.com - Investing.com South Africa
Bionano Genomics Appoints Dr. Alex Hastie as Chief Scientific Officer to Drive Innovation in Optical Genome Mapping - Minichart
Bionano Genomics Appoints Alex Hastie as Chief Scientific Officer - Quiver Quantitative
Bionano appoints Alex Hastie as Chief Scientific Officer to lead global science strategy - TradingView
Bionano Announces Hiring of Chief Scientific Officer - marketscreener.com
Alex Hastie returns as Chief Scientific Officer at Bionano Genomics (NASDAQ: BNGO) - Stock Titan
Bionano brings back OGM pioneer to lead science strategy July 20 - Stock Titan
Bionano Genomics Inc (BNGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BNGO Q1 2026 Earnings: EPS Surprises to the Upside Amid Continued Operational ChallengesEPS Revision Trend - dars.gov.et
Bionano Genomics (BNGO) Slips 1.72% as Stock Tests Key Support LevelsFactor Momentum - DonanımHaber
Bionano Genomics (BNGO) Sees Significant Growth in Optical Genome Mapping Studies - GuruFocus
Bionano Genomics reports 67% increase in studies at genetics conference - Investing.com
Bionano Genomics reports 67% increase in studies at genetics conference By Investing.com - Investing.com Canada
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption - The Manila Times
Bionano’s genome-mapping studies jump to 35 at ESHG 2026 - Stock Titan
Bionano Genomics Inc (BNGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bionano Genomics Inc (BNGO) Institutional Confidence - TradingKey
Bionano Genomics Inc (BNGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bionano Genomics (BNGO) Slides Amid Light Volume, Testing Support at $1.10Dealer Positioning - dars.gov.et
Bionano Genomics Keeps Penny Stock Risk In Focus - Kalkine Media
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders - The Manila Times
바이오나노 지노믹스 (BNGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.37%
0.55%
자본화:
|
볼륨(24시간):